Stock News Cara Therapeutics initiates phase 2 study of its main candidate for the treatment of pruritus ottous January 13, 2021 0 Comments Cara Therapeutics initiates phase 2 study of its main candidate for the treatment of pruritus Related Posts:Moderna’s stock extends rally as experts await…Novartis Phase 4 Migraine Study Meets EndpointGSK's investigational COVID-19 treatment Vir enters…The study of ADHD drugs from Supernus Pharma met the…
